Sol Shenker

2.8k total citations · 1 hit paper
16 papers, 1.4k citations indexed

About

Sol Shenker is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sol Shenker has authored 16 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 5 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Sol Shenker's work include CRISPR and Genetic Engineering (6 papers), RNA Research and Splicing (6 papers) and RNA modifications and cancer (5 papers). Sol Shenker is often cited by papers focused on CRISPR and Genetic Engineering (6 papers), RNA Research and Splicing (6 papers) and RNA modifications and cancer (5 papers). Sol Shenker collaborates with scholars based in United States. Sol Shenker's co-authors include Eric C. Lai, Pedro Miura, Jakub Orzechowski Westholm, Piero Sanfilippo, Brenton R. Graveley, S Celniker, Sara Olson, Brian Joseph, Celia Andreu-Agulló and Jiayu Wen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Genome Research.

In The Last Decade

Sol Shenker

16 papers receiving 1.4k citations

Hit Papers

Genome-wide Analysis of Drosophila Circular RNAs Reveals ... 2014 2026 2018 2022 2014 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sol Shenker United States 8 1.3k 793 50 46 45 16 1.4k
Minna‐Liisa Änkö Australia 15 876 0.7× 226 0.3× 57 1.1× 56 1.2× 25 0.6× 27 1.0k
Irmgard U. Haussmann United Kingdom 16 1.3k 1.0× 511 0.6× 137 2.7× 128 2.8× 51 1.1× 29 1.5k
Andrei Filipchyk Germany 6 1.3k 1.0× 993 1.3× 30 0.6× 31 0.7× 17 0.4× 6 1.4k
Rémy Bordonné France 22 1.6k 1.2× 134 0.2× 45 0.9× 65 1.4× 61 1.4× 42 1.7k
Sarah H. Carl Switzerland 10 893 0.7× 301 0.4× 20 0.4× 56 1.2× 46 1.0× 13 947
Paulina Galka-Marciniak Poland 15 607 0.5× 311 0.4× 100 2.0× 43 0.9× 28 0.6× 19 702
T. K. Rajendra United States 13 845 0.6× 82 0.1× 45 0.9× 44 1.0× 73 1.6× 16 921
Natalie G. Farny United States 11 895 0.7× 118 0.1× 44 0.9× 144 3.1× 56 1.2× 16 997
Qijia Wu China 10 882 0.7× 372 0.5× 75 1.5× 37 0.8× 64 1.4× 21 1.0k
Javier Armisen United Kingdom 13 803 0.6× 620 0.8× 33 0.7× 71 1.5× 106 2.4× 15 1.0k

Countries citing papers authored by Sol Shenker

Since Specialization
Citations

This map shows the geographic impact of Sol Shenker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sol Shenker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sol Shenker more than expected).

Fields of papers citing papers by Sol Shenker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sol Shenker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sol Shenker. The network helps show where Sol Shenker may publish in the future.

Co-authorship network of co-authors of Sol Shenker

This figure shows the co-authorship network connecting the top 25 collaborators of Sol Shenker. A scholar is included among the top collaborators of Sol Shenker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sol Shenker. Sol Shenker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Dodson, Anne E., Sol Shenker, Pamela Sullivan, et al.. (2024). Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. Cancer Research Communications. 4(12). 3084–3098. 1 indexed citations
2.
Tobin, Erica R., Pamela Sullivan, Hugh Gannon, et al.. (2023). Abstract 1581: KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity with multiple PARP inhibitors in BRCA mutant cancers. Cancer Research. 83(7_Supplement). 1581–1581. 2 indexed citations
3.
Sullivan, Pamela, Yuji Mishina, Anne E. Dodson, et al.. (2023). Abstract 2771: KSQ-4279 mediated USP1 inhibition induces replication associated DNA gaps that contribute to cell death. Cancer Research. 83(7_Supplement). 2771–2771. 1 indexed citations
4.
Lin, Sharon, Leila J. Williams, Hugh Gannon, et al.. (2022). 255 ExPRESSTM: An accelerated process for the manufacture of KSQ-001, a CRISPR/Cas9-edited eTILTM product. Regular and Young Investigator Award Abstracts. A270–A270. 1 indexed citations
5.
Shenker, Sol, Hugh Gannon, Paula Grasberger, et al.. (2021). Abstract 1337: Functional genomic characterization of the USP1 inhibitor KSQ-4279 reveals a distinct mechanism of action and resistance profile relative to other DDR targeting drugs. Cancer Research. 81(13_Supplement). 1337–1337. 7 indexed citations
6.
Wong, Karrie, Sharon Lin, Isabelle Le Mercier, et al.. (2021). 204 KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors. Regular and Young Investigator Award Abstracts. A215–A215. 3 indexed citations
7.
Wong, Karrie, Sharon Lin, Leila J. Williams, et al.. (2021). 186 Development of KSQ-001, an engineered TIL (eTIL) therapy for solid tumors through CRISPR/Cas9-mediated editing of SOCS1. SHILAP Revista de lepidopterología. A198–A198. 1 indexed citations
8.
Sullivan, Richard, Sol Shenker, Michael McGuire, et al.. (2020). Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers. European Journal of Cancer. 138. S52–S52. 15 indexed citations
9.
Wen, Jiayu, Erik Ladewig, Sol Shenker, Jaaved Mohammed, & Eric C. Lai. (2015). Analysis of Nearly One Thousand Mammalian Mirtrons Reveals Novel Features of Dicer Substrates. PLoS Computational Biology. 11(9). e1004441–e1004441. 58 indexed citations
10.
Shenker, Sol, Pedro Miura, Piero Sanfilippo, & Eric C. Lai. (2014). IsoSCM: improved and alternative 3′ UTR annotation using multiple change-point inference. RNA. 21(1). 14–27. 46 indexed citations
11.
Westholm, Jakub Orzechowski, Pedro Miura, Sara Olson, et al.. (2014). Genome-wide Analysis of Drosophila Circular RNAs Reveals Their Structural and Sequence Properties and Age-Dependent Neural Accumulation. Cell Reports. 9(5). 1966–1980. 774 indexed citations breakdown →
12.
Miura, Pedro, Piero Sanfilippo, Sol Shenker, & Eric C. Lai. (2014). Alternative polyadenylation in the nervous system: To what lengths will 3′ UTR extensions take us?. BioEssays. 36(8). 766–777. 49 indexed citations
13.
Miura, Pedro, Sol Shenker, Celia Andreu-Agulló, Jakub Orzechowski Westholm, & Eric C. Lai. (2013). Widespread and extensive lengthening of 3′ UTRs in the mammalian brain. Genome Research. 23(5). 812–825. 251 indexed citations
14.
Smibert, Peter, Pedro Miura, Jakub Orzechowski Westholm, et al.. (2013). Global Patterns of Tissue-Specific Alternative Polyadenylation in Drosophila. Cell Reports. 3(3). 969–969. 2 indexed citations
15.
Smibert, Peter, Pedro Miura, Jakub Orzechowski Westholm, et al.. (2012). Global Patterns of Tissue-Specific Alternative Polyadenylation in Drosophila. Cell Reports. 1(3). 277–289. 187 indexed citations
16.
Spitzer, Walter O., Sol Shenker, & Gerry Hill. (1982). Cancer in a Montreal suburb: the investigation of a nonepidemic.. PubMed. 127(10). 971–4. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026